ANGLE signs option agreement with Queen Mary University of London

Josh White WebFG News | 13 Sep, 2017 14:48 | | |

cash money sterling pound

Angle

40.50

17:17 17/11/17
0.62%
0.25
  • 7,896.56
  • -0.17%-13.73
  • Max: 7,935.84
  • Min: 7,890.25
  • Volume: 0
  • MM 200 : n/a
17:18 17/11/17
  • 1,023.43
  • 0.18%1.82
  • Max: 1,023.88
  • Min: 1,021.32
  • Volume: 0
  • MM 200 : n/a
17:25 17/11/17

Liquid biopsy company ANGLE announced that it has signed an option agreement with Queen Mary University of London on Wednesday, for an exclusive worldwide licence over the use of its megakaryocyte intellectual property.

The AIM-traded firm said in June that QMUL had published research in Clinical Cancer Research using ANGLE's Parsortix system, showing that the number of megakaryocyte cells in the blood of prostate cancer patients correlated closely with increased patient survival.

It was the first time the presence of those cells in patient blood had been shown to be connected to cancer prognosis, ANGLE claimed.

“Investigation of megakaryocytes in patient blood opens up the potential for a whole new area for cancer diagnostics and, at present, ANGLE's patented Parsortix system is the only system that has demonstrated the capability of harvesting megakaryocytes,” the company’s board said in its statement.

QMUL had filed two patent applications in relation to the findings, which were being prosecuted worldwide.

ANGLE said it signed a two-year option to an exclusive worldwide licence to the patents covering any medical therapeutic, diagnostic, or prophylactic application, and agreeing to cover the costs of prosecution.

Through the deal, ANGLE now had intellectual property protection over the upstream cell capture technology - its existing Parsortix IP - and the downstream megakaryocyte analysis technology - via the option agreement.

Megakaryocyte analysis may provide medical insight in multiple cancer types, the board added, and Barts Cancer Institute - which is part of QMUL - is investigating other cancer types to substantiate that.

ANGLE said the Parsortix system had been shown to be capable of harvesting for analysis not only mesenchymal CTCs, which are linked to a poor outcome, but also megakaryocytes, which are linked to a “favourable” patient outcome.

Combining those two factors could provide new insights into patient condition.

“This deal further strengthens ANGLE's intellectual property position in the fast-emerging liquid biopsy market,” said ANGLe founder and chief executive Andrew Newland.

“Use of the Parsortix system is driving new discoveries by key opinion leaders and customers and ANGLE is the obvious partner to drive their commercialisation so we expect to see other similar developments over time continually strengthening the Company's position in the market.”

Michele Hill-Perkins, head of technology transfer biopharma at QMUL Barts Queen Mary Innovation, said her team believed the patents on the role of megakaryocytes in patient blood as a favourable prognostic biomarker had the potential to “open up” new avenues of research in the fight against cancer.

“We are delighted to have signed this deal with ANGLE to progress their commercialisation for the benefit of patients.”

More news

17 Nov Europe close: Stocks slip going into the weekend

Stocks reversed early gains as investors opted to play it safe going into the weekend and the euro edged a tad higher on the back of the political gyrations on Capitol Hill.

17 Nov Europe open: Stocks start slightly higher, analysts wary

Stocks have started the morning trading slightly higher, tracking overnight gains on Wall Street but analysts are worried about buying into Thursday's bounce.

17 Nov London close: Stocks finish week on down note

London's top flight index slipped on Friday, but managed to finish well-off its lows of the session despite renewed Brexit angst as the pound gave back early gains.

17 Nov Kingfisher gets RBC upgrade as 'reasons to be cheerful' in France

DIY retailer Kingfisher has more "reasons to be cheerful" thanks to an improving French outlook, analysts at RBC Capital Markets said on Friday, while clothes seller Supergroup remains "compelling" but its shares have gained a lot in recent weeks.

17 Nov NAV on the rise as Alpha Real Estate Trust turns focus to build-to-rent market

Real estate investment group Alpha Real Trust saw its net asset value (NAV) rise in its first half of trading as it moved to make further investments in build-to-rent projects.

17 Nov Pacific Industrial & Logistics completes sale of Bedford asset

Industrial and logistics-focussed real estate investment trust Pacific Industrial & Logistics has completed the sale of an asset located at Hammond Road, Bedford, for a total consideration of £5.8m, it announced on Friday.

17 Nov DP Poland cuts ribbon on 50th Polish Domino's store

DP Poland, which holds the exclusive master franchise for the Domino’s Pizza brand in Poland, celebrated the opening of its 50th location in the country on Friday.

17 Nov Mercia Technologies makes new investment into Aston EyeTech

National investment group Mercia Technologies has made a new direct investment into Aston EyeTech - a spinout from Aston University, Birmingham - which has developed a range of proprietary hardware and software products in ocular care, it announced on Friday.

17 Nov SimiGon receives final approval for $2m Israeli Air Force order

Modelling, simulation and training solutions provider SimiGon has now received final regulatory approval for a $2m purchase order received from the Israeli Air Force, initially announced on 20 June 2016, it confirmed on Friday.

17 Nov Agriterra losses grow after 'subdued' interest in corn products

Agricultural investment group Agriterra saw losses widen in the first half of its trading year as subdued demand for its maize flour products slashed revenues by more than a third.